Boundless Bio IPO Presentation Deck
March 2024, 51 slides
  1. Boundless Bio
  2. Related Decks
  3. IPO Presentation Decks
aby boundless unlocking a new paradigm in cancer treatment via directed therapies | Boundless Bio
disclaimer and forward looking statements | Boundless Bio
offering details | Boundless Bio
boundless clinical stage company establishing a new category in oncology that addresses amplified cancers via targeting | Boundless Bio
are cancer specific circular units of that are a frequent driver of amplified cancer core am toe amplified corn i next frontier of oncology mig | Boundless Bio
next generation precision oncology pipeline targets to address high unmet need cancer patients | Boundless Bio
accomplished leadership team has proven experience delivering value for patients and shareholders fate sierra lan | Boundless Bio
company is supported by premier board members advisors and investors leaps vertex | Boundless Bio
significant unmet need in amplified cancers | Boundless Bio
cancers with amplifications more aggressive difficult to treat and worse prognosis | Boundless Bio
despite advancements in precision medicine targeted therapies cancers with gene amplifications generally do not respond to lot | Boundless Bio
across most patients with gene amplified tumors derive little benefit from targeted therapies | Boundless Bio
boundless was formed to deliver a new therapeutic approach for patients with amplified cancers by targeting the underlying biology mise boundless founded series a series series | Boundless Bio
a key driver of amplifications | Boundless Bio
are a primary driver of amplified cancers and enable resistance to targeted therapies | Boundless Bio
are detected broadly across different cancer types but not in normal tissue or blood | Boundless Bio
cancer most common high copy number amplifications frequently occur on when they do it is associated with worse survival | Boundless Bio
enable cancer cells to resist therapies by rapidly adapting dependency a rode | Boundless Bio
tumors employ to rapidly enable new drivers even under combination target inhibition sie a | Boundless Bio
driving a new treatment paradigm by targeting pathways that enable tumor evolution and resistance traditional targeted therapy game over | Boundless Bio
spyglass platform fuels new therapeutic approach by advancing directed therapies to patients | Boundless Bio
spyglass unique platform for interrogating driven tumors proprietary target and drug candidate discovery engine unmet need proprietary platform boundless innovation | Boundless Bio
spyglass reveals cancer targets both novel and validated that intersect distinct nodes of | Boundless Bio
echo novel investigational diagnostic test designed to detect using routine clinical data non significant risk determination granted by for use in phase potentiate trial of stem echo | Boundless Bio
the in phase potentiate trial targeting induced replication stress via inhibition | Boundless Bio
amplified cancer cells have significantly elevated replication stress amplified amplified a | Boundless Bio
inhibition of kinase is synthetic lethal in cancer cells is a master regulator of the response | Boundless Bio
novel selective oral inhibitor designed to disrupt and overcome limitations of prior and existing inhibitors data a sierra ase strategy | Boundless Bio
demonstrated single agent activity across a wide variety of amplified tumor models | Boundless Bio
demonstrated synergistic combination activity in preclinical models of cancer indications in which single agent targeted therapies have not proven effective in the clinic eye | Boundless Bio
demonstrated proof of concept in multiple additional addicted models cest | Boundless Bio
phase study of designed to drive to clinical proof of concept in multiple settings | Boundless Bio
human preliminary data of shows dose proportionality and achieving exposures in the predicted therapeutically active range at sere aerials at | Boundless Bio
summary of interim safety data drug related aes subjects dose dependent on target toxicity observed toxicity consistent with prior inhibitors i | Boundless Bio
evidence of pharmacodynamic activity observed in clinical samples across dose levels me me | Boundless Bio
projected for patient enrollment to potential clinical and beyond | Boundless Bio
phase trial open for enrollment targeting assembly repair via | Boundless Bio
amplifications often on are a frequent mechanism of clinical resistance to multiple therapeutic modalities | Boundless Bio
our second is a novel reductase inhibitor that targets the assembly and repair of a | Boundless Bio
selective inhibition of with resulted in depletion reduced and in amplified cancer cells | Boundless Bio
demonstrated synthetic lethality in combination with kras inhibition in kras addicted cancer both preventing and treating resistance post emergence | Boundless Bio
overcame amplification based resistance to treatment of cells in | Boundless Bio
phase study of will evaluate prevention and treatment of amplification mediated resistance to pathway inhibitors mutation and | Boundless Bio
pathway amplification mediated acquired resistance initial croc inhibitors tan | Boundless Bio
boundless unique investment opportunity in new area of cancer biology targeting large unmet need | Boundless Bio
seeking to address amplification market by targeting agnostic nodes of biology | Boundless Bio
boundless a compelling and differentiated investment opportunity node anticipated milestones | Boundless Bio
boundless a breakthrough company leading the next wave of innovation in cancer treatment cancer treatment breakthroughs eat | Boundless Bio
boundless unbound by convention bound to save lives | Boundless Bio
bibliography of recent reviews and publications covering active | Boundless Bio
boundless and represent very different propositions | Boundless Bio
See More
Boundless Bio
IPO Presentation Decks
Biotechnology Decks
Healthcare Decks
Explore Topics
Cancer
Tumor
Inhibitor
Related decks
Nuvalent
Investor Presentation
May 2023
Erasca
Investor Presentation
August 2023
Nuvectis Pharma
Investor Presentation
August 2023
Nuvectis Pharma
Investor Presentation
July 2023
BioAtla
IPO
December 2020
Nuvectis Pharma
Investor Presentation
January 2024
Allarity Therapeutics
Investor Conference
September 2022
Alkermes
Investor Day
March 2021
Nuvalent
Investor Presentation
May 2023
Erasca
Investor Presentation
August 2023
Nuvectis Pharma
Investor Presentation
August 2023
Nuvectis Pharma
Investor Presentation
July 2023
BioAtla
IPO
December 2020
Nuvectis Pharma
Investor Presentation
January 2024
Allarity Therapeutics
Investor Conference
September 2022
Alkermes
Investor Day
March 2021
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io